Simone Seiter
Director/Board Member at GENSIGHT BIOLOGICS S.A.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Laurence Rodriguez | F | 56 | 3 years | |
| Michael Wyzga | M | 69 | 11 years | |
| Florent Gros | M | 56 |
Priothera SAS
 Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | 4 years |
| Brice R. Suire | M | - |
Priothera SAS
Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | 4 years |
| Maritza McIntyre | M | 58 | 5 years | |
| Françoise de Craecker | F | 62 | 3 years | |
| Stephan Oehen | M | 56 |
Priothera SAS
Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | 4 years |
| Elsy Boglioli Hofman | F | 42 | 4 years | |
| Magali Taiel | M | - | 6 years | |
| Philippe Lievre | M | - |
Priothera SAS
Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | 4 years |
| Jonathan Morris | M | - |
IQVIA
| 11 years |
| Cédric Moreau | M | 37 | 5 years | |
| Julio Benedicto | M | - | 7 years | |
| Marion Ghibaudo | M | - | 3 years | |
| Sissel Rodahl | F | - | 2 years | |
| Scott Jeffers | M | - | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Bernard Gilly | M | 67 | 12 years | |
| Peter Goodfellow | M | 72 | 9 years | |
| Natalie Mount | M | - | 4 years | |
| Andreas Bender | M | - |
IQVIA
| 2 years |
| Cem Baydar | M | - |
IQVIA
| 8 years |
| Didier Pruneau | M | 68 | 5 years | |
| Barrett Katz | M | 74 | 2 years | |
| Guido Magni | M | 70 | 6 years | |
| Harvey N. Masonson | M | - | 1 years | |
| Maïlys Ferrère | F | 60 | 3 years | |
| Thomas Gidoin | M | 41 | 9 years | |
| Earl Collier | M | 76 | - | |
| Mohamed Genead | M | - | - | |
| Genghis Lloyd-Harris | M | 67 | 5 years | |
| Charlotte Corbaz | F | - | - | |
| Isabelle Pengue-Koyi | M | - | 6 years | |
| Isabelle Scarabin | F | - | 8 years | |
| Philippe Motté | M | 64 | - | |
| Leigh Shaw | M | - | 2 years | |
| Clothilde Caillet | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| France | 33 | 91.67% |
| Germany | 3 | 8.33% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Simone Seiter
- Personal Network